acetaminophen and Multiple Sclerosis, Relapsing-Remitting
acetaminophen has been researched along with Multiple Sclerosis, Relapsing-Remitting in 5 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
Multiple Sclerosis, Relapsing-Remitting: The most common clinical variant of MULTIPLE SCLEROSIS, characterized by recurrent acute exacerbations of neurologic dysfunction followed by partial or complete recovery. Common clinical manifestations include loss of visual (see OPTIC NEURITIS), motor, sensory, or bladder function. Acute episodes of demyelination may occur at any site in the central nervous system, and commonly involve the optic nerves, spinal cord, brain stem, and cerebellum. (Adams et al., Principles of Neurology, 6th ed, pp903-914)
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
"Naproxen and ibuprofen were more effective than acetaminophen in minimizing physical side effects of IFN beta-1a." | 6.71 | A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis. ( Filipi, M; Healey, K; Leuschen, MP, 2004) |
"To assess dose-response effects of the anti-CD20 monoclonal antibody ofatumumab on efficacy and safety outcomes in a phase 2b double-blind study of relapsing forms of multiple sclerosis (RMS)." | 2.87 | Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study. ( Austin, DJ; Bar-Or, A; Derosier, FJ; Grove, RA; Kavanagh, ST; Lewis, EW; Lopez, MC; Miller, AE; Sorensen, PS; Tolson, JM; VanMeter, SA, 2018) |
"Naproxen and ibuprofen were more effective than acetaminophen in minimizing physical side effects of IFN beta-1a." | 2.71 | A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis. ( Filipi, M; Healey, K; Leuschen, MP, 2004) |
Research
Studies (5)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 4 (80.00) | 29.6817 |
2010's | 1 (20.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Bar-Or, A | 1 |
Grove, RA | 1 |
Austin, DJ | 1 |
Tolson, JM | 1 |
VanMeter, SA | 1 |
Lewis, EW | 1 |
Derosier, FJ | 1 |
Lopez, MC | 1 |
Kavanagh, ST | 1 |
Miller, AE | 1 |
Sorensen, PS | 1 |
Río, J | 1 |
Nos, C | 1 |
Bonaventura, I | 1 |
Arroyo, R | 1 |
Genis, D | 1 |
Sureda, B | 1 |
Ara, JR | 1 |
Brieva, L | 1 |
Martín, J | 1 |
Saiz, A | 1 |
Sánchez López, F | 1 |
Prieto, JM | 1 |
Roquer, J | 1 |
Dorado, JF | 1 |
Montalban, X | 1 |
Leuschen, MP | 1 |
Filipi, M | 1 |
Healey, K | 1 |
Brandes, DW | 1 |
Bigley, K | 1 |
Hornstein, W | 1 |
Cohen, H | 1 |
Au, W | 1 |
Shubin, R | 1 |
Reess, J | 1 |
Haas, J | 1 |
Gabriel, K | 1 |
Fuhlrott, A | 1 |
Fiola, M | 1 |
Clinical Trials (3)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Randomized, Double-blind, Placebo-controlled, Parallel-Group, Dose-Ranging Study to Investigate the MRI Efficacy and Safety of Six Months' Administration of Ofatumumab in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)[NCT01457924] | Phase 2 | 232 participants (Actual) | Interventional | 2011-11-01 | Completed | ||
Impact of Ocrelizumab on Cerebrospinal Fluid Biomarkers at Multiple Sclerosis Onset[NCT04466150] | Phase 4 | 30 participants (Anticipated) | Interventional | 2020-08-30 | Active, not recruiting | ||
A Trial of Prednisone and Acetaminophen Versus Acetaminophen Alone in Minimizing Flu-like Symptoms From Pegylated Interferon Beta-1a[NCT03424733] | Phase 4 | 50 participants (Anticipated) | Interventional | 2017-09-25 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trial Outcomes
Cumulative Number of All (New Plus Persistent) GdE Brain Lesions on T1-weighted MRI at Week 12
The cumulative number of all (new plus persistent) GdE T1 lesion at Week 12 were analyzed from screen based on MRI brain scans at Weeks 4, 8 and 12. Anticipating an underlying negative binomial distribution with a log-link function, adjusted for treatment and presence/absence of GdE lesions on the Screening MRI. Treatment group was fitted as a categorical variable. The number of scans contributing to the cumulative number of lesions was fitted as an offset. Estimates of the rate of cumulative number of all (new plus persistent) GdE T1 lesions per scan at Week 12 were determined from the model. The AES dataset was used which included all evaluable on-treatment MRI scans for each par. analyzed. (NCT01457924)
Timeframe: Week 12
Intervention | Cumulative number of lesions (Mean) |
---|---|
Placebo/Ofatumumab 3 mg | 7.4 |
Ofatumumab 3 mg q12w | 2.9 |
Ofatumumab 30 mg q12w | 4.5 |
Ofatumumab 60 mg q12w | 4.0 |
Ofatumumab 60mg q4w | 3.1 |
Cumulative Number of New and Newly Enlarging GdE T2 Lesions at Week 12
The cumulative number of new and newly enlarging GdE T2 lesions (NET2L) at Week 12 were analyzed from screen based on MRI brain scans at Weeks 4, 8 and 12. The endpoint was analyzed using a generalized linear model assuming an underlying negative binomial distribution with a log-link function, adjusted for treatment and presence/absence of GdE lesions on the Screening MRI. Treatment group was fitted as a categorical variable. The number of scans contributing to the cumulative number of lesions was fitted as an offset. Estimates of the rate of cumulative number of NET2L per scan at Week 12 were determined from the model. The AES dataset was used which included all evaluable on-treatment MRI scans for each par. analyzed. (NCT01457924)
Timeframe: Week 12
Intervention | Cumulative number of lesions (Mean) |
---|---|
Placebo/Ofatumumab 3 mg | 3.7 |
Ofatumumab 3 mg q12w | 1.2 |
Ofatumumab 30 mg q12w | 1.6 |
Ofatumumab 60 mg q12w | 1.7 |
Ofatumumab 60mg q4w | 0.8 |
Cumulative Number of New Gadolinium-enhancing (GdE) T1 Lesions at Week 12
The cumulative number of new GdE T1 lesion at Week 12 were analyzed from screening based on magnetic resonance imaging (MRI) brain scans at Weeks 4, 8, and 12. The outcome measure was analyzed using an Emax model adjusting for the presence/absence of GdE lesions on the Screening MRI and assuming the number of new lesions followed a negative binomial distribution. Dose was fitted as a continuous variable. The number of scans contributing to the cumulative number of lesions was fitted as an offset. Estimates of the rate of cumulative number of new GdE lesions per scan at Week 12 were determined from the model. The all evaluable scans (AES) dataset was used which included all evaluable on-treatment MRI scans for each participant analysed. (NCT01457924)
Timeframe: Week 12
Intervention | Cumulative number of lesions (Mean) |
---|---|
Placebo/Ofatumumab 3 mg | 4.2 |
Ofatumumab 3 mg q12w | 1.7 |
Ofatumumab 30 mg q12w | 2.2 |
Ofatumumab 60 mg q12w | 2.2 |
Ofatumumab 60mg q4w | 1.2 |
Cumulative Number of New GdE T1 Lesions at Week 24
The cumulative number of new GdE T1 lesion at Week 24 were analyzed from screen based on MRI brain scans at Weeks 4, 8, 12, 16, 20 and 24. Anticipating an underlying negative binomial distribution with a log-link function, adjusted for treatment and presence/absence of GdE lesions on the Screening MRI. Treatment group was fitted as a categorical variable. The number of scans contributing to the cumulative number of lesions was fitted as an offset. Estimates of the rate of cumulative number of new GdE T1 lesions per scan at Week 24 were determined from the model. The AES dataset was used which included all evaluable on-treatment MRI scans for each participant analyzed. (NCT01457924)
Timeframe: Week 24
Intervention | Cumulative number of lesions (Mean) |
---|---|
Placebo/Ofatumumab 3 mg | 5.6 |
Ofatumumab 3 mg q12w | 2.2 |
Ofatumumab 30 mg q12w | 2.5 |
Ofatumumab 60 mg q12w | 2.2 |
Ofatumumab 60mg q4w | 1.4 |
Cumulative Number of Persistent GdE Brain Lesions on T1-weighted MRI at Week 12
The cumulative number of persistent GdE T1 lesions at Week 12 were analyzed from screen based on MRI scans at Weeks 4, 8, and 12. The AES dataset was used which included all evaluable on-treatment MRI scans for each par. analyzed. (NCT01457924)
Timeframe: Week 12
Intervention | Number of lesions per scan (Mean) |
---|---|
Placebo/Ofatumumab 3 mg | 3.2 |
Ofatumumab 3 mg q12w | 1.2 |
Ofatumumab 30 mg q12w | 2.3 |
Ofatumumab 60 mg q12w | 1.8 |
Ofatumumab 60mg q4w | 1.8 |
Total Volume of All (New and Persistent) GdE Brain Lesions on T1-weighted MRI at Week 12
Lesion volume is a measure of lesion size determined by a MRI brain scan. The cumulative volume of all (new and persistent) GdE T1 lesions at Week 12 were analyzed from screen based on MRI brain scans at Weeks 4, 8 and 12. The endpoint was analyzed using a generalized linear model assuming an underlying negative binomial distribution with a log-link function, adjusted for treatment and presence/absence of GdE lesions on the Screening MRI. Treatment group was fitted as a categorical variable. The number of scans contributing to the cumulative volume of lesions was fitted as an offset. Estimates of the rate of cumulative volume of all (new and persistent) GdE T1 lesions per scan at Week 12 were determined from the model. The AES dataset was used which included all evaluable on-treatment MRI scans for each par. analyzed. (NCT01457924)
Timeframe: Week 12
Intervention | mm^3 (Mean) |
---|---|
Placebo/Ofatumumab 3 mg | 1039.6 |
Ofatumumab 3 mg q12w | 386.2 |
Ofatumumab 30 mg q12w | 886.2 |
Ofatumumab 60 mg q12w | 426.5 |
Ofatumumab 60mg q4w | 344.4 |
Total Volume of New and/or Newly Enlarging T2 Lesions at Week 12
Lesion volume is a measure of lesion size determined by a MRI brain scan. T2 lesions, are indicative of brain myelin content.The cumulative volume of new and/or newly enlarging T2 lesions at Week 12 were analyzed from screen based on MRI brain scans at Weeks 4, 8, and 12. The AES dataset was used which included all evaluable on-treatment MRI scans for each par. (NCT01457924)
Timeframe: Week 12
Intervention | mm^3 (Mean) |
---|---|
Placebo/Ofatumumab 3 mg | 1204.5 |
Ofatumumab 3 mg q12w | 279.9 |
Ofatumumab 30 mg q12w | 611.3 |
Ofatumumab 60 mg q12w | 293.8 |
Ofatumumab 60mg q4w | 167.9 |
Total Volume of New GdE Brain Lesions on T1-weighted MRI at Week 12
Lesion volume is a measure of lesion size determined by a MRI brain scan. The cumulative volume of new GdE T1 lesions at Week 12 were analyzed from screen based on MRI brain scans at Weeks 4, 8 and 12. Anticipating an underlying negative binomial distribution with a log-link function, adjusted for treatment and presence/absence of GdE lesions on the Screening MRI. Treatment group was fitted as a categorical variable. The number of scans contributing to the cumulative volume of lesions was fitted as an offset. Estimates of the rate of cumulative volume of new GdE T1 lesions per scan at Week 12 were determined from the model. The AES dataset was used which included all evaluable on-treatment MRI scans for each par. analyzed. (NCT01457924)
Timeframe: Week 12
Intervention | Cubic millimeter (mm^3) (Mean) |
---|---|
Placebo/Ofatumumab 3 mg | 607.5 |
Ofatumumab 3 mg q12w | 226.5 |
Ofatumumab 30 mg q12w | 452.9 |
Ofatumumab 60 mg q12w | 248.6 |
Ofatumumab 60mg q4w | 146.6 |
Change From Baseline in Brain Volume at Week 24 and Week 48
Brain volume is a measure of brain size determined by a MRI scan. Baseline is defined as the par. last available assessment prior to initiation of the IP (i.e. Screening). Change from Baseline was calculated by subtracting the Baseline value from the post-Baseline value. (NCT01457924)
Timeframe: Baseline (Week 0), Week 24 and Week 48
Intervention | Cubic centimeters (Mean) | |
---|---|---|
Week 24 | Week 48 | |
Ofatumumab 3 mg q12w | -7.2 | -12.9 |
Ofatumumab 30 mg q12w | -8.4 | -5.0 |
Ofatumumab 60 mg q12w | -13.3 | -7.3 |
Ofatumumab 60mg q4w | -1.4 | -11.8 |
Placebo/Ofatumumab 3 mg | -13.5 | -22.0 |
Cumulative Number of New T1 Hypointense Lesions at Week 24 and Week 48
The cumulative number of new T1 hypointense lesions at week 24 were analyzed from screen based on MRI brain scans at Weeks 4, 8, 12, 16, 20 and 24. The AES dataset was used which included all evaluable on-treatment MRI scans for each par. (NCT01457924)
Timeframe: Week 24 and Week 48
Intervention | Number of lesions (Mean) | |
---|---|---|
Week 24 | Week 48 | |
Ofatumumab 3 mg q12w | 0.4 | 0.5 |
Ofatumumab 30 mg q12w | 0.5 | 0.5 |
Ofatumumab 60 mg q12w | 0.5 | 0.6 |
Ofatumumab 60mg q4w | 0.3 | 0.3 |
Placebo/Ofatumumab 3 mg | 0.4 | 0.6 |
Cumulative Volume of New T1 Hypointense Lesions at Week 24 and Week 48
Lesion volume is a measure of lesion size determined by a MRI brain scan. Baseline is defined as the participant's last available assessment prior to initiation of IP. Change from Baseline was calculated by subtracting the Baseline value from the post-Baseline value. The AES dataset was used which included all evaluable on-treatment MRI scans for each par. (NCT01457924)
Timeframe: Baseline, Week 24 and Week 48
Intervention | mm^3 (Mean) | |
---|---|---|
Week 24 | Week 48 | |
Ofatumumab 3 mg q12w | 43.1 | 54.2 |
Ofatumumab 30 mg q12w | 67.4 | 63.2 |
Ofatumumab 60 mg q12w | 65.0 | 116.3 |
Ofatumumab 60mg q4w | 42.9 | 53.2 |
Placebo/Ofatumumab 3 mg | 86.9 | 113.6 |
Trials
5 trials available for acetaminophen and Multiple Sclerosis, Relapsing-Remitting
Article | Year |
---|---|
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Antibo | 2018 |
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Antibo | 2018 |
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Antibo | 2018 |
Subcutaneous ofatumumab in patients with relapsing-remitting multiple sclerosis: The MIRROR study.
Topics: Acetaminophen; Administration, Oral; Adult; Analgesics, Non-Narcotic; Antibodies, Monoclonal; Antibo | 2018 |
Corticosteroids, ibuprofen, and acetaminophen for IFNbeta-1a flu symptoms in MS: a randomized trial.
Topics: Acetaminophen; Adult; Analgesics, Non-Narcotic; Asthenia; Chills; Double-Blind Method; Drug Administ | 2004 |
A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFN beta-1a therapy and during its ongoing use for relapsing-remitting multiple sclerosis.
Topics: Acetaminophen; Adjuvants, Immunologic; Adult; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, No | 2004 |
Alleviating flu-like symptoms with dose titration and analgesics in MS patients on intramuscular interferon beta-1a therapy: a pilot study.
Topics: Acetaminophen; Adjuvants, Immunologic; Adolescent; Adult; Aged; Analgesics, Non-Narcotic; Drug Thera | 2007 |
Both paracetamol and ibuprofen are equally effective in managing flu-like symptoms in relapsing-remitting multiple sclerosis patients during interferon beta-1a (AVONEX) therapy.
Topics: Acetaminophen; Adult; Chills; Female; Fever; Headache; Humans; Ibuprofen; Interferon beta-1a; Interf | 2002 |